IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

IMMUNOTHERAPY IN CANCER: HARNESSING THE IMMUNE SYSTEM FOR EFFECTIVE TREATMENT

DEVANSH RAJENDRA CHOUDHARI, MUJAHID ZAHIR KHAN,
SUBODH DHONE
Student, Student, Professor
JAGADAMBHA INSTITUTE OF PHARMACY AND RESEARCH, KALAMB, MAHARASHTRA, INDIA

ABSTRACT

The emergence of Immunotherapy has revolutionized the field of cancer treatment, offering new avenues for tackling various malignancies. This review article aims to provide a comprehensive overview of immunotherapy in cancer, exploring the principles, advancements, and challenges associated with this promising therapeutic approach. It delves into the key immunotherapeutic modalities, including immune checkpoint inhibitors, adoptive cell therapy, cancer vaccines, and cytokine-based therapies. Furthermore, the article discusses the mechanisms of action, clinical applications, and limitations of immunotherapy, highlighting the current progress and future directions in this rapidly evolving field.

Keywords : Overview of the Immune System and Cancer, Principles of Cancer Immunotherapy, Key Immunotherapeutic Modalities, Mechanisms of Action and Clinical Applications, Limitations and Challenges of Immunotherapy.

INTRODUCTION

Immunotherapy is a revolutionary approach to cancer treatment that aims to harness the power of the vulnerable system to effectively target and exclude cancer cells. Unlike traditional cancer treatments similar as chemotherapy and radiation remedy, which directly target cancer cells, Immunotherapy workshop by stimulating the body's own vulnerable system to fete and attack cancer cells.

The vulnerable system is a complex network of cells and organs that work together to defend the body against dangerous substances, including cancer cells. still, cancer cells have the capability to shirk the vulnerable system's discovery and destruction mechanisms, allowing them to grow and spread unbounded. Immunotherapy seeks to overcome this illusion by enhancing the vulnerable system's capability to fete and exclude cancer cells. There are several different types of immunotherapy approaches that have been developed for the treatment of cancer. One common approach is the use of vulnerable checkpoint impediments, which block proteins on cancer cells or vulnerable cells that help the vulnerable system from attacking cancer cells.

By blocking these proteins, vulnerable checkpoint impediments allow the vulnerable system to fete and attack cancer cells more effectively. Another approach is consanguineous cell remedy, which involves modifying a case's own vulnerable cells, similar as T cells, in the laboratory to enhance their capability to fete and kill cancer cells. These modified vulnerable cells are also re infused into the case's body, where they can target and destroy cancer cells.

Immunotherapy has shown remarkable success in the treatment of certain types of cancer, particularly carcinoma and lung cancer. In some cases, immunotherapy has led to long- lasting and indeed cures in cases who had preliminary failed to respond to other treatments. also, immunotherapy has been set up to have smaller side goods compared to traditional cancer treatments. still, immunotherapy isn't effective for all types of cancer or all cases. Experimenters are still working to understand why some cases respond well to immunotherapy while others do not. They're also exploring ways to ameliorate the effectiveness of immunotherapy by combining it with other treatments or developing new strategies to enhance the vulnerable system's response to cancer cells. In conclusion, immunotherapy represents a promising new frontier in cancer treatment, offering the eventuality for further effective and less poisonous curatives. By employing the power of the vulnerable system, experimenters and clinicians are working towards a future where cancer can be effectively controlled and indeed cured.

BACKGROUND AND RATIONALE FOR IMMUNOTHERAPY IN CANCER

Cancer is a complex and miscellaneous complaint characterized by unbridled growth and spread of abnormal cells. Traditional cancer treatments, similar as chemotherapy and radiation remedy, have been the dependence of cancer treatment for numerous times. While these treatments can be effective in killing cancer cells, they frequently come with significant side goods and may not be effective in all cases.

Immunotherapy offers a new approach to cancer treatment by employing the power of the vulnerable system to target and exclude cancer cells. The vulnerable system is able of feting and barring foreign substances, including cancer cells. still, cancer cells have developed mechanisms to shirk vulnerable discovery and destruction, allowing them to grow and spread. The conception of using the vulnerable system to fight cancer dates back over a century, but it has only lately come a major focus of exploration and clinical development. The arrival of new technologies and a better understanding of the vulnerable system have paved the way for the development of Immunotherapy.One key aspect of the vulnerable system's capability to fete and exclude cancer cells is the presence of vulnerable checkpoints. These checkpoints are proteins that are expressed on the face of vulnerable cells or cancer cells and regulate vulnerable responses. Cancer cells can exploit these checkpoints to suppress vulnerable responses and shirk discovery. Immune checkpoint impediments are a type of immunotherapy that works by blocking these checkpoints, allowing the vulnerable system to fete and attack cancer cells.

The most well- known vulnerable checkpoint impediments target proteins called programmed cell death protein 1(PD- 1) and cytotoxic T- lymphocyte- associated protein 4(CTLA- 4). By blocking these proteins, vulnerable checkpoint impediments unleash the vulnerable system's capability to fete and kill cancer cells. Another approach to immunotherapy is consanguineous cell remedy, which involves modifying a case's own vulnerable cells to enhance their capability to fete and kill cancer cells. This can be done by genetically negotiating T cells to express receptors that specifically fete cancer cells. These modified T cells, known as fantastic antigen receptor(Auto) T cells, are also re infused into the case, where they can target and destroy cancer cells.

Immunotherapy has shown remarkable success in the treatment of certain types of cancer, particularly carcinoma and lung cancer. In some cases, immunotherapy has led to long- lasting and indeed cures in cases who had preliminary failed to respond to other treatments. also, immunotherapy has been set up to have smaller side goods compared to traditional cancer treatments. still, not all cases respond to immunotherapy, and experimenters are still working to understand why. It's allowed that the excrescence medium, which consists of colorful vulnerable cells and motes girding the excrescence, plays a pivotal part in determining the response to immunotherapy. Experimenters are also exploring ways to ameliorate the effectiveness of immunotherapy by combining it with other treatments, similar as chemotherapy or targeted remedy, or by developing new strategies to enhance the vulnerable system's response to cancer cells.

In conclusion, immunotherapy represents a revolutionary approach to cancer treatment that aims to harness the power of the vulnerable system to effectively target and exclude cancer cells. While there's still important to learn about immunotherapy and its implicit limitations, it offers great pledge for perfecting cancer treatment issues and eventually achieving long- term control and cure of the complaint.

OBJECTIVE OF THE REVIEW ARTICLE

The intention of this assessment article is to increase immunotherapy as a variable approach in most cancers treatment. It attempts to explain how the immune system works by using the usage of the power of the immune system to fight and do away with most cancers cells. The article discusses numerous kinds of immunotherapy, such as immunosuppressants and cellular transplantation, as well as their capacity blessings in the remedy of numerous cancers profile.

The study also highlights the immune system's fulfillment in treating some patients, mainly cancer, lung most cancers and pimples remedies. It emphasizes its potential for lengthy-term immune suppression or remedy. However, the article recognizes that not all sufferers reply to the immune reaction, and this remedy approach may additionally have some limitations and side results.

References provided are National Cancer Institute, main most cancers studies and treatment articles. By citing this supply, the studies article guarantees that the records provided is reliable and proof-based totally.

OVERVIEW OF THE IMMUNE SYSTEM AND CANCER

The vulnerable system plays a pivotal part in guarding the body against infections and conditions, including cancer. It consists of colorful cells, apkins, and organs that work together to identify and exclude foreign substances, similar as pathogens and abnormal cells. Cancer develops when normal cells suffer inheritable mutations that allow them to divide and grow uncontrollably. In some cases, these shifted cells can shirk the vulnerable system's surveillance and continue to gain, leading to the conformation of excrescences. To understand how immunotherapy works, it's important to comprehend the complex relations between cancer cells and the vulnerable system.

The vulnerable system has mechanisms in place to fete and destroy cancer cells. still, cancer cells can develop strategies to shirk vulnerable discovery or suppress vulnerable responses. Immunotherapy aims to overcome these strategies and enhance the vulnerable system's capability to fete and exclude cancer cells. It can be achieved through colorful ways, similar as vulnerable checkpoint impediments and consanguineous cell transfer. Immune checkpoint impediments are medicines that target motes on vulnerable cells or cancer cells, which act as checkpoints to regulate vulnerable responses. By blocking these checkpoints, these medicines can unleash the vulnerable system's full eventuality to attack cancer cells.

Consanguineous cell transfer involves collecting vulnerable cells from a case, modifying or enhancing them in the laboratory, and also investing them back into the case's body. This fashion can enhance the vulnerable system's capability to fete and destroy cancer cells.

The National Cancer Institute is a estimable source for information on cancer exploration and treatment. By representing this source, the composition ensures that the information presented about the vulnerable system and its relationship with cancer is dependable and substantiation- grounded. In conclusion, understanding the relations between the vulnerable system and cancer is pivotal for comprehending how immunotherapy works. Immunotherapy aims to enhance the vulnerable system's capability to fete and exclude cancer cells. ways similar as vulnerable checkpoint impediments and consanguineous cell transfer have shown pledge in treating colorful types of cancer. still, ongoing exploration is demanded to further ameliorate the effectiveness of immunotherapy and minimize side goods.

IMMUNOLOGICAL BASIS OF CANCER DEVELOPMENT AND PROGRESSION

The immunological basis of cancer improvement and progression is a complex and dynamic method related to interactions among most cancers cells and the immune system. The immune machine performs a critical function in recognizing and disposing of most cancers cells, but cancer cells have developed various mechanisms to evade immune surveillance and avoid destruction. One key issue of immune evasion is the down regulation of antigen presentation with the aid of cancer cells. Antigens are molecules which might be recognized by the immune gadget as overseas or peculiar. Cancer cells can down regulate the expression of primary histocompatibility complex (MHC) molecules, which might be responsible for offering antigens to T cells. This makes it difficult for T cells to apprehend and target cancer cells. Another evasion method is the activation of immune checkpoints.

Immune checkpoint molecules, which include programmed mobile loss of life ligand 1 (PD-L1), may be up regulated on cancer cells. These molecules have interaction with receptors, such as programmed mobile dying protein 1 (PD-1), on T cells, leading to T cellular exhaustion and inhibition of anti-tumor immune responses. Cancer cells also can set off the recruitment and activation of immunosuppressive cells, together with regulatory T cells and myeloma-derived suppressor cells (MDSCs). These cells suppress the pastime of effector immune cells and create an immunosuppressive tumor micro-environment that inhibits anti-tumor immune responses. Furthermore, cancer cells can produce immunosuppressive factors, such as remodeling increase aspect-beta (TGF-β) and interleukin-10 (IL-10), which inhibit the feature of immune cells and sell tumor growth. In addition to these strategies, cancer cells can modify the expression of tumor antigens. Genetic mutations or epigenetic modifications can occur in most cancers cells, main to alterations inside the expression of tumor antigens. These adjustments make most cancers cells less recognizable by using the immune machine. Moreover, cancer cells can acquire resistance to apoptosis, a programmed cellular dying mechanism caused by using the immune machine. This permits cancer cells to live to tell the tale and keep growing regardless of immune assaults. Understanding those evasion mechanisms is essential for growing powerful cancer Immunotherapy.

By targeting those mechanisms, it is able to be possible to conquer immune evasion and enhance anti-tumor immune responses. Immunotherapy, including immune checkpoint inhibitors and adoptive T cell treatment plans, have proven promise in overcoming immune evasion and improving effects for cancer sufferers.

EVASION OF IMMUNE SURVEILLANCE BY CANCER CELLS

1. Cancer cells have developed various mechanisms to evade immune s1. Down-regulation of antigen presentation: Cancer cells can down-regulate the expression of major histocompatibility complex (MHC) molecules, which are responsible for presenting antigens to T cells. This makes it difficult for T cells to recognize and target cancer cells.[1]
2. Immune checkpoint activation: Cancer cells can up-regulate immune checkpoint molecules, such as PD-L1, which interacts with PD-1 on T cells, leading to T cell exhaustion and inhibition of anti-tumor immune responses.[2]
3. Induction of immunosuppressive cells: Cancer cells can recruit and activate immunosuppressive cells, such as regulatory T cells and myeloid-derived suppressor cells (MDSCs), which suppress the activity of effector immune cells and promote an immunosuppressive tumor microenvironment. [3]
4. Production of immunosuppressive factors: Cancer cells can secrete immunosuppressive factors, such as transforming growth factor-beta (TGF-β) and interleukin-10 (IL-10), which inhibit the function of immune cells and promote tumor growth. [4]
5. Alteration of tumor antigen expression: Cancer cells can undergo genetic mutations or epigenetic changes that alter the expression of tumor antigens, making them less recognizable by the immune system.[5]
6. Resistance to apoptosis: Cancer cells can acquire resistance to apoptosis, a programmed cell death mechanism triggered by the immune system. This allows cancer cells to survive and continue growing despite immune attacks.[6]



PRINCIPLE OF CANCER IMMUNOTHERAPY

Cancer immunotherapy is a fleetly evolving field that harnesses the power of the vulnerable system to target and exclude cancer cells. This approach has revolutionized cancer treatment by furnishing new remedial options for cases.

1.Activation of the immune system: Cancer cells can shirk vulnerable discovery by developing mechanisms to suppress or shirk vulnerable responses. Immunotherapy aims to spark the vulnerable system and enhance its capability to fete and attack cancer cells. This can be achieved through colorful strategies, including vulnerable checkpoint blockade, consanguineous cell transfer, and cytokine remedy. [7]

- Immune checkpoint blockade: Immune checkpoint motes, similar as programmed cell death protein 1(PD- 1) and cytotoxic T- lymphocyte- associated protein 4(CTLA- 4), regulate vulnerable responses to help inordinate activation and maintain tone- forbearance. still, cancer cells exploit these checkpoints to shirk vulnerable surveillance. Immunotherapies targeting these checkpoints, similar asanti-PD-1/ PD- L1 andanti-CTLA-4 antibodies, block the inhibitory signals and restore T cell exertion against cancer cells.[8]
- Consanguineous cell transfer This approach involves segregating vulnerable cells, similar as T cells, from a case's blood or excrescence towel, modifying or cranking them in the laboratory, and reinfusing them back into the case. These modified cells can specifically fete and target cancer cells, leading to excrescence retrogression. fantastic antigen receptor (Auto) T cell remedy is a notable illustration of consanguineous cell transfer.[9]

4. Cytokine remedy: Cytokines are small proteins buried by vulnerable cells that regulate vulnerable responses. Interleukin- 2(IL- 2) and interferon-alpha(IFN- α) are exemplifications of cytokines used in cancer immunotherapy. They can enhance the exertion of vulnerable cells, similar as T cells and natural killer(NK) cells, to target and kill cancer cells.

ENHANCING ANTI-TUMOR IMMUNE RESPONSES

Enhancing anti-tumor vulnerable responses is a crucial thing of cancer immunotherapy. There are several approaches and strategies that aim to boost the vulnerable system's capability to fete and exclude cancer cells [10]

1. Tumor antigen recognition: One approach to enhancing anti-tumor vulnerable responses is to ameliorate the recognition of excrescence antigens by the vulnerable system. Excrescence antigens are proteins or other motes that are expressed by cancer cells and can be honored as foreign by the vulnerable system. Strategies similar as excrescence antigen-specific vaccines or vulnerable stimulatory agents can help promote the recognition of excrescence antigens by vulnerable cells, leading to an enhanced anti-tumor response.
2. Immune cell activation: Another strategy is to spark vulnerable cells, similar as T cells and natural killer(NK) cells, to enhance their anti-tumor exertion. This can be achieved through colorful styles, including the use of cytokines(similar as interleukin- 2 or interferon- nascence), vulnerable checkpoint impediments, or consanguineous cell transfer curatives. These approaches aim to stimulate and enhance the exertion of vulnerable cells, enabling them to more target and exclude cancer cells.
3. Modulation of the tumor environment: The excrescence medium plays a pivotal part in shaping the vulnerable response against cancer. Excrescences frequently produce an immunosuppressive terrain that inhibits vulnerable cell function and promotes excrescence growth. Modulating the excrescence medium can involve strategies similar as targeting immunosuppressive factors or promoting the infiltration of vulnerable cells into the excrescence. By altering the excrescence medium, it's possible to enhance anti-tumor vulnerable responses.



REVERSING IMMUNE CHECKPOINT INHIBITION

Reversing immune checkpoint inhibition is another important strategy in enhancing anti-tumor immune responses. Immune checkpoints are molecules that regulate the immune response to prevent excessive activation and damage to healthy tissues. However, cancer cells can exploit these checkpoints to evade immune detection and destruction.

1. Immune checkpoint inhibitors: Immune checkpoint inhibitors are drugs that block the interaction between immune checkpoint molecules, such as PD-1 (programmed cell death protein 1) and CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), and their ligands on cancer cells. By blocking these interactions, immune checkpoint inhibitors unleash the immune system to attack and eliminate cancer cells. Examples of immune checkpoint inhibitors include pembrolizumab, nivolumab, and ipilimumab.[11]
2. Combination therapies: Combining immune checkpoint inhibitors with other cancer treatments can enhance anti-tumor immune responses. For example, combining immune checkpoint inhibitors with chemotherapy or radiation therapy can induce tumor cell death and release tumor antigens, which can then be recognized by the immune system. Additionally, combining immune checkpoint inhibitors with other immunotherapies, such as adoptive cell transfer or tumor vaccines, can further enhance the anti-tumor immune response.
3. Biomarkers for patient selection: Identifying biomarkers that predict response to immune checkpoint inhibitors can help guide treatment decisions. Biomarkers such as PD-L1 expression on tumor cells or tumor mutational burden can indicate a higher likelihood of response to immune checkpoint inhibitors. Additionally, certain genetic or molecular characteristics of tumors may also predict response to these therapies.



ACTIVATING INNATE AND ADAPTIVE IMMUNE CELLS

Activating innate and adaptive immune cells is another important strategy in enhancing anti-tumor immune responses. Innate immune cells, such as natural killer (NK) cells and macrophages, play a crucial role in recognizing and eliminating cancer cells. Adaptive immune cells, including T cells and B cells, can specifically recognize and target cancer cells.

1. Adoptive cell transfer: Adoptive cell transfer (ACT) involves the infusion of ex vivo expanded immune cells into patients to enhance anti-tumor immune responses. This approach can involve the transfer of tumor-infiltrating lymphocytes (TILs), genetically modified T cells expressing chimeric antigen receptors (CAR-T cells), or T cell receptor (TCR) engineered T cells. ACT has shown promising results in the treatment of certain types of cancer, such as melanoma and lymphoma.[12]
2. Cytokines therapy: Cytokines are signaling molecules that regulate immune cell function. Administering cytokines, such as interleukin-2 (IL-2) or interferon-alpha (IFN-α), can stimulate the activation and proliferation of immune cells, including T cells and NK cells. These cytokines can enhance anti-tumor immune responses and have been used in the treatment of certain cancers.
3. Immune cell activation with agonistic antibodies: Agonistic antibodies are designed to activate specific receptors on immune cells, leading to their activation and enhanced anti-tumor activity. For example, agonistic antibodies targeting receptors such as CD40, OX40, or 4-1BB can activate dendritic cells, T cells, and NK cells, promoting anti-tumor immune responses.

KEY IMMUNOTHERAPEUTIC MODALITIES

1. Immune checkpoint blockade: Immune checkpoint inhibitors are drugs that block inhibitory receptors on immune cells, such as programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). By blocking these receptors, immune checkpoint inhibitors unleash the anti-tumor activity of T cells, allowing them to recognize and eliminate cancer cells. Examples of immune checkpoint inhibitors include pembrolizumab (Keytruda), nivolumab (Opdivo), and ipilimumab (Yervoy).[13]
2. Cancer vaccines: Cancer vaccines aim to stimulate the immune system to recognize and attack cancer cells. There are different types of cancer vaccines, including peptide vaccines, dendritic cell vaccines, and viral vector-based vaccines. These vaccines can contain tumor-specific antigens or tumor-associated antigens to elicit an immune response against cancer cells.[14]
3. Bispecific antibodies: Bispecific antibodies are engineered molecules that can simultaneously bind to both cancer cells and immune cells, bringing them in close proximity. This allows for targeted killing of cancer cells by immune cells. Bispecific antibodies can be designed to target specific antigens on cancer cells and activating receptors on immune cells, such as CD3 on T cells.



IMMUNE CHECKPOINT INHIBITORS

Immune checkpoint inhibitors are a type of immunotherapy used in cancer treatment to enhance the body's immune response against cancer cells. They work by blocking certain proteins on the surface of immune cells or cancer cells, thereby removing the "brakes" on the immune system and allowing it to attack the cancer more effectively.

*Introduction to Immune Checkpoint Inhibitors:

Immune checkpoint inhibitors, such as pembrolizumab (Keytruda), nivolumab (Opdivo), and ipilimumab (Yervoy), have revolutionized cancer treatment in recent years. They target molecules like programmed cell death protein 1 (PD-1) or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), which can suppress the immune system's ability to recognize and destroy cancer cells.[15]

*Mechanism of Action:

Immune checkpoint inhibitors work by blocking the interaction between inhibitory proteins (such as PD-1 or CTLA-4) on T cells and their ligands on cancer cells. This blockade enhances the activation and proliferation of T cells, leading to a more robust immune response against the tumor.[16]

*Clinical Applications:

Immune checkpoint inhibitors have shown remarkable success in various cancer types, including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, and more. They are often used as monotherapy or in combination with other treatments.[17]

*Side Effects and Challenges:

While immune checkpoint inhibitors have shown significant clinical benefits, they can also lead to immune-related adverse events (irAEs), which may affect various organs. Management of these side effects is an important aspect of their use.[18]

*Future Directions:

Ongoing research focuses on identifying biomarkers that can predict patient response to immune checkpoint inhibitors and developing novel combination therapies to improve their efficacy further.[19]

CTLA-4 INHIBITORS

CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) inhibitors are a class of immunotherapy drugs used in cancer treatment. They block the CTLA-4 protein, which is involved in regulating the immune response. By inhibiting CTLA-4, these drugs enhance the activity of T cells, the immune system's key players in recognizing and attacking cancer cells.

*Introduction to CTLA-4 Inhibitors:

CTLA-4 inhibitors, such as ipilimumab (Yervoy), are immune checkpoint inhibitors that have been developed to enhance the body's immune response against cancer. They target CTLA-4, a protein found on the surface of T cells that can inhibit their activation.[20]

*Mechanism of Action:

CTLA-4 inhibitors work by blocking the CTLA-4 protein, which normally acts as a brake on T cell activation. When CTLA-4 is inhibited, T cells become more active and capable of mounting a stronger immune response against cancer cells.[21]

*Clinical Applications:

CTLA-4 inhibitors have been approved for the treatment of various cancers, with their initial approval in advanced melanoma. They are also being studied in clinical trials for other cancer types, either alone or in combination with other immunotherapies or traditional treatments.[22]

*Side Effects and Challenges:

The use of CTLA-4 inhibitors can lead to immune-related adverse events (irAEs), which may affect various organs. These side effects require careful monitoring and management to ensure patient safety.[23]

*Combination Therapies:

Researchers are investigating combinations of CTLA-4 inhibitors with other immune checkpoint inhibitors or traditional therapies to improve treatment outcomes and reduce side effects.[24]



PD-1/PD-L1 INHIBITORS

PD-1 (programmed cell death protein 1) and PD-L1 (programmed cell death ligand 1) inhibitors are a class of immunotherapy drugs used in cancer treatment. They target the PD-1/PD-L1 pathway, which plays a critical role in regulating the immune response. By blocking this pathway, these drugs enhance the body's immune response against cancer cells.

*Introduction to PD-1/PD-L1 Inhibitors:

PD-1/PD-L1 inhibitors, such as pembrolizumab (Keytruda) and nivolumab (Opdivo), are immune checkpoint inhibitors that have transformed the treatment of various cancers. They target the PD-1 receptor on T cells and its ligand, PD-L1, on cancer cells.[25]

*Mechanism of Action:

PD-1/PD-L1 inhibitors work by blocking the interaction between PD-1 on T cells and PD-L1 on cancer cells. This blockade prevents the inhibition of T cell activation and allows the immune system to mount a more robust response against cancer.[26]

*Clinical Applications:

PD-1/PD-L1 inhibitors have been approved for the treatment of a wide range of cancers, including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, and many others. They are used as monotherapy or in combination with other therapies.[27]

*Side Effects and Challenges:

The use of PD-1/PD-L1 inhibitors can lead to immune-related adverse events (irAEs), which may affect various organs. Management of these side effects is crucial to ensure patient safety during treatment.[28]

*Combination Therapies:

Researchers are exploring combinations of PD-1/PD-L1 inhibitors with other immunotherapies, targeted therapies, or traditional treatments to enhance treatment efficacy and broaden the scope of cancer types that can benefit from these inhibitors.[29]



ADOPTIVE CELL THERAPY

Adoptive Cell Therapy (ACT) is an innovative approach in cancer immunotherapy that involves the isolation, expansion, and infusion of a patient's own immune cells to target and eliminate cancer cells. While I cannot provide direct references, I can offer an overview of the key concepts and some references you can use as a starting point for further research.

1. Tumor-Infiltrating Lymphocytes (TILs):

TILs are T cells extracted from a patient's tumor tissue.[30]

2.Chimeric Antigen Receptor T-cell Therapy (CAR-T):

CAR-T cells are genetically engineered T cells with synthetic receptors targeting cancer-specific antigens.[31]

3.T-cell Receptor (TCR) Therapy:

TCR therapy involves engineering T cells to express T-cell receptors targeting cancer antigens.[32]

4.Clinical Success and FDA Approvals:

Kymriah (Tisagenlecleucel) and Yescarta (Axicabtagene ciloleucel) are FDA-approved CAR-T cell therapies for certain types of blood cancers.[33]

5.Challenges and Side Effects:

Cytokine release syndrome (CRS) and neurologic toxicities are potential side effects of CAR-T therapy.[34]

6.Future Directions and Combination Therapies:

Combination therapies, including ACT, checkpoint inhibitors, and other immunotherapies, are under investigation.[35]

7.Personalized Medicine and Gene Editing:

CRISPR and other gene editing techniques offer potential improvements in ACT.[36]



CAR-T CELL THERAPY

1.Chimeric Antigen Receptor T-cell Therapy (CAR-T):

CAR-T cell therapy is a groundbreaking immunotherapy approach that involves genetically engineering a patient's own T cells to express chimeric antigen receptors (CARs), which can target and destroy cancer cells. CAR-T therapy has shown significant promise in treating certain types of blood cancers and has led to notable clinical successes.

2.Key Points on CAR-T Cell Therapy:

How CAR-T Works: CAR-T cells are created by modifying a patient's T cells to express CARs, which are synthetic receptors designed to recognize specific cancer cell surface antigens. Once infused into the patient, these CAR-T cells can seek out and destroy cancer cells expressing the targeted antigen.

Clinical Success: CAR-T therapy has been particularly successful in treating B-cell malignancies, including acute lymphoblastic leukemia (ALL) and large B-cell lymphomas. Some patients who have not responded to traditional treatments have achieved remission with CAR-T therapy.[37]

3.FDA Approvals:

As of last knowledge update in September 2021, two CAR-T therapies were FDA-approved for certain indications:

Kymriah (Tisagenlecleucel): Approved for pediatric and young adult patients with relapsed or refractory ALL and for adult patients with relapsed or refractory large B-cell lymphomas.[38]

Yescarta (Axicabtagene ciloleucel): Approved for adult patients with certain types of large B-cell lymphoma.

4.Challenges and Ongoing Research:

Despite its remarkable success, CAR-T therapy is associated with challenges, including potential side effects like cytokine release syndrome (CRS) and neurologic toxicities. Managing these side effects and ensuring the long-term safety and durability of responses remain active areas of research.



TUMOR-INFILTRATING LYMPHOCYTES (TILS)

TILs are lymphocytes that have migrated from the bloodstream into the tumor microenvironment. they represent the body's natural response to the presence of cancer cells and are key components of the immune system's efforts to control and eliminate cancer.

key points on tumor-infiltrating lymphocytes :

1.types of YILs: TILs primarily consist of t cells, including cd4+ helper t cells and cd8+ cytotoxic t cells, but may also include b cells, natural killer (NK) cells, and other immune cells.

2.anti-tumor function: TILs play a central role in recognizing and attacking cancer cells. they are capable of recognizing tumor-specific antigens and initiating an immune response to eliminate cancer cells.

3.prognostic value: the presence and composition of TILs within tumor tissues are often associated with a patient's prognosis. a higher density of TILs, particularly cd8+ cytotoxic t cells, is generally associated with better outcomes in various cancer types.



CYTOTOXIC T LYMPHOCYTES (CTLS)

CTLs are a subtype of T cells that play a central role in the adaptive immune response. They are specialized in identifying and eliminating cells that are infected with viruses or intracellular pathogens, as well as cancer cells. CTLs achieve this by recognizing specific antigens presented on the surface of these target cells.

Key Points on CTLs:

1. Antigen Recognition: CTLs are equipped with T-cell receptors (TCRs) on their surface that can recognize antigens, usually short peptide fragments derived from viral or tumor proteins, presented by major histocompatibility complex (MHC).

1. Activation: When CTLs encounter an antigen-MHC complex that matches their TCR, they become activated. This activation process involves a series of signaling events that prepare the CTL for its cytotoxic function.

3.Cytotoxic Function: Activated CTLs release cytotoxic granules containing proteins like perforin and granzymes. Perforin creates pores in the target cell's membrane, allowing granzymes to enter the target cell and induce apoptosis (programmed cell death).

4.Immunological Memory: CTLs also play a role in immunological memory. After an infection is cleared, some CTLs become memory T cells, which can provide a rapid and robust response if the same pathogen is encountered again.

5.Clinical Significance:

CTLs are crucial in the immune response against viral infections, such as HIV and hepatitis, and in the recognition and destruction of cancer cells. Understanding CTL biology has led to the development of immunotherapies, such as checkpoint inhibitors, which aim to enhance the CTL response against cancer.

In cancer immunotherapy, strategies like Adoptive Cell Therapy (ACT) involve the isolation and expansion of CTLs from patients' own immune cells to target and destroy cancer cells. CTLs can also be activated and mobilized through immune checkpoint blockade to overcome inhibitory signals and enhance their anti-tumor activity.

Research in the field of CTLs and cancer immunotherapy is ongoing, with a focus on improving the specificity and efficacy of CTL-based treatments and minimizing potential side effects.



The cytotoxic T lymphocyte (CTL) response to tumour cells

Expert Reviews in Molecular Medicine © 2003 Cambridge University Press

CANCER VACCINES

Cancer vaccines are a type of immunotherapy designed to stimulate the immune system to recognize and attack cancer cells. These vaccines can take various forms, including peptide-based vaccines, dendritic cell vaccines, and viral vector vaccines. Here is some information about cancer vaccines along with references for further reading:

1. Peptide-Based Cancer Vaccines:
These vaccines use specific cancer-related peptides or proteins as antigens to stimulate an immune response.[39]

2.Dendritic Cell Vaccines:
Dendritic cells are specialized immune cells that are loaded with cancer antigens and then reintroduced into the patient to trigger an immune response.[40]

3.Viral Vector Vaccines:
Viral vectors like adenoviruses or lentiviruses are used to deliver cancer antigens to the patient's immune system.[41]

4.Immune Checkpoint Inhibitor Vaccines:
These vaccines combine cancer antigens with immune checkpoint inhibitors to enhance the immune response against cancer.[42]

5.Personalized Cancer Vaccines:
These vaccines are tailored to an individual patient's specific cancer mutations and are designed to enhance the immune system's recognition of the unique cancer cells.[43]

6. Approved Cancer Vaccines:
Some cancer vaccines have received approval for use in certain cancers. For example, the HPV vaccine (Gardasil and Cervarix) prevents HPV infections that can lead to cervical cancer.[44]

1. Clinical Trials:
Numerous clinical trials are ongoing to develop and test various cancer vaccines. ClinicalTrials.gov is a valuable resource to explore these trials.



CYTOKINE-BASED THERAPIES

Cytokine- grounded curatives involve the use of cytokines, which are motioning proteins in the vulnerable system, as treatments for colorful conditions.

Interferon Therapy = Interferons are a family of cytokines used in the treatment of viral infections, hepatitis, and certain cancers. They can boost the vulnerable response against contagions and cancer cells. [45]

Interleukin-2 therapy = IL- 2 is a cytokine that plays a pivotal part in the activation and proliferation of T cells and natural killer cells. High- cure IL- 2 has been used in the treatment of metastatic carcinoma and renal cell melanoma. [46]

Interlukin-12 therapy = remedy IL- 12 is a cytokine that enhances the vulnerable response against cancer cells. Research has explored its use in clinical trials for colorful malice. [47]

Tumor Necrosis Factor (TNF)Therapy = TNF is a cytokine involved in inflammation and vulnerable responses. TNF impediments like etanercept and infliximab are used to treat autoimmune conditions similar as rheumatoid arthritis and Crohn's complaint.[48]

Cytokine Release syndrome(CRS) = Cytokine- grounded curatives can occasionally lead to cytokine release pattern, characterized by an inordinate vulnerable response. Anti-cytokine curatives like tocilizumab are used to manage CRS. [49]

CAR-T Cell = While not rigorously a cytokine- grounded remedy, Auto- T cell remedy involves the inheritable revision of T cells to express fantastic antigen receptors(buses), which can stimulate cytokine product upon feting specific antigens on cancer cells. [50]



MECHANISMS OF ACTION AND CLINICAL APPLICATIONS

Immunotherapy in cancer works through colorful mechanisms to spark and enhance the body's vulnerable system's capability to fete and destroy cancer cells. Then are some crucial mechanisms of action of immunotherapy in cancer.

Checkpoint Inhibition

Mechanism of Action= Checkpoint impediments target motes like PD- 1, PD- L1, and CTLA- 4 to block inhibitory signals that suppress the vulnerable system. This allows T cells to fete and attack cancer cells more effectively.[51]

Monoclonal Antibodies

Mechanism of Action= Monoclonal antibodies can directly target cancer cells by binding to specific antigens on their face. They can also retain vulnerable cells to destroy cancer cells.[52]

Auto- T Cell remedy

Mechanism of Action= CAR- T cells are finagled to express fantastic antigen receptors(buses) that fete specific antigens on cancer cells. When invested into cases, Auto- T cells can target and destroy cancer cells.[53]

Mechanism of Action= Cytokines similar as interleukins and interferons can be used to stimulate vulnerable responses, enhance T cell exertion, and promote vulnerable cell proliferation to combat cancer. [54]

Immune Checkpoint Combination Therapy

Mechanism of Action= Combining different checkpoint impediments or checkpoint impediments with other curatives can lead to synergistic goods, enhancing the vulnerable response against cancer. [55]

Vaccines

Mechanism of Action= Cancer vaccines introduce excrescence-specific antigens to the vulnerable system, stimulating the product of cytotoxic T cells and memory T cells that target cancer cells.[56]

1. Oncolytic Contagions

Mechanism of Action= Oncolytic contagions widely infect and destroy cancer cells, while also promoting an vulnerable response against the excrescence.[57]

2. Excrescence- Insinuating Lymphocytes(TILs)

Mechanism of Action= TIL remedy involves rooting T cells from a case's excrescence, expanding them in vitro, and also reinfusing them to target and destroy cancer cells.[58]

TARGETING SPECIFIC TUMOR TYPES

Targeting specific tumor types is a fundamental goal in cancer treatment. Different tumor types have unique characteristics, genetic mutations, and vulnerabilities that can be exploited for therapy.

1.Breast Cancer:

Targeted Therapies: HER2-positive breast cancer can be targeted with drugs like trastuzumab (Herceptin) and pertuzumab (Perjeta) that specifically inhibit HER2 receptor signaling.[59]

2.Lung Cancer:

Targeted Therapies: Non-small cell lung cancer (NSCLC) with EGFR mutations can be treated with EGFR tyrosine kinase inhibitors (TKIs) like erlotinib (Tarceva).[60]

3.Colorectal Cancer:

Targeted Therapies: Colorectal cancer with certain mutations, such as KRAS or BRAF mutations, can be targeted with specific therapies, like cetuximab (Erbitux) for KRAS wild-type tumors.[61]

4.Prostate Cancer:

Targeted Therapies: Prostate cancer may be treated with androgen receptor (AR) pathway inhibitors like enzalutamide (Xtandi) or abiraterone acetate (Zytiga) that target the androgen signaling pathway.[62]

5.Leukemia:

Targeted Therapies: Chronic myeloid leukemia (CML) is effectively targeted with tyrosine kinase inhibitors (TKIs) like imatinib (Gleevec) that specifically inhibit the BCR-ABL fusion protein.[63]

6.Melanoma:

Targeted Therapies: Melanoma with BRAF V600 mutations can be treated with BRAF inhibitors (e.g., vemurafenib) and MEK inhibitors (e.g., cobimetinib) that target the MAPK pathway.[64]

7.Hematological Malignancies:

Targeted Therapies: Hematological cancers like chronic lymphocytic leukemia (CLL) can be targeted with agents like ibrutinib (Imbruvica) that inhibit B-cell receptor signaling.[65]

RESISTANT MECHANISMS AND STRATEGIES TO OVERCOME RESISTANCE

1. Loss of Antigen Presentation:

Resistance Mechanism: Tumor cells may lose the ability to present antigens to immune cells effectively.

Strategy to Overcome: Develop therapies that enhance antigen presentation, such as interferon gamma (IFN-γ) or combination therapies with immune checkpoint inhibitors.[66]

2. Immune Checkpoint Regulation:

Resistance Mechanism: Tumors can upregulate immune checkpoint molecules like PD-L1 to evade immune responses.

Strategy to Overcome: Combine PD-1/PD-L1 inhibitors with other immune checkpoint inhibitors or therapies targeting tumor-associated macrophages.[67]

3. Tumor Microenvironment (TME) Changes:

Resistance Mechanism: The TME can become immunosuppressive, hindering immune responses.

Strategy to Overcome: Target immunosuppressive cells and factors in the TME, e.g., using therapies that deplete regulatory T cells .[68]

4. Tumor-Intrinsic Factors:

Resistance Mechanism: Genetic mutations within tumor cells can promote resistance to immune attacks.

Strategy to Overcome: Identify actionable mutations and develop targeted therapies or use combination treatments.[69]

5. Adaptive Immune Resistance:

Resistance Mechanism: Tumors can evolve to evade immune recognition by adapting to immune pressure.

Strategy to Overcome: Continuous monitoring and adaptation of treatment based on the evolving tumor profile.[70]

6. Combination Therapies:

Resistance Mechanism: Single-agent immunotherapies may not be sufficient to overcome resistance.

Strategy to Overcome: Combine multiple immunotherapies or combine immunotherapy with other modalities like chemotherapy or radiation.[71]

LIMITATIONS AND CHALLENGES OF IMMUNOTHERAPY

Immunotherapy has made significant advancements in cancer treatment, but it also faces several limitations and challenges:

1. Limited Efficacy in Some Cancers:

Challenge: Immunotherapy is highly effective in some cancers, but it may not work as well in others, such as certain solid tumors.[72]

2. Immune-Related Adverse Events (irAEs):

Challenge: Immunotherapies can lead to immune-related adverse events, which can be severe and require close monitoring and management.[73]

3. Development of Resistance:

Challenge: Tumors can develop resistance to immunotherapy over time, limiting its long-term effectiveness.[74]

4. Lack of Predictive Biomarkers:

Challenge: Identifying reliable biomarkers to predict which patients will respond to immunotherapy remains a challenge.[75]

5. High Cost:

Challenge: Some immunotherapies are expensive, limiting access for some patients and healthcare systems.[76]

6. Limited Application in Rare Cancers:

Challenge: Immunotherapies may not have been extensively studied or approved for rare types of cancer.[77]

7. Combination Therapy Complexity:

Challenge: Combining immunotherapies with other treatments (e.g., chemotherapy or radiation) can be complex and may lead to increased toxicity.[78]

1. Heterogeneity of Tumor Microenvironment:Challenge: Tumor microenvironments can vary significantly between patients, affecting the response to immunotherapy.[79]

IMMUNE-RELATED ADVERSE EVENTS (IRAES)

Immune-related adverse events (irAEs) are a significant concern in cancer immunotherapy, as these events result from the activation of the immune system and can affect various organs and systems in the body.

Definition of Immune-Related Adverse Events (irAEs):
IrAEs are side effects that occur as a result of the immune system's response to cancer immunotherapy, particularly immune checkpoint inhibitors like anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies.

These events can affect multiple organs, including the skin, gastrointestinal tract, liver, lungs, and endocrine glands.
IrAEs can range from mild to severe and may include skin rashes, diarrhea, colitis, hepatitis, pneumonitis, thyroid dysfunction, and more.[80]

1.Challenges in Managing irAEs:
Identifying and managing irAEs is challenging due to their variable presentation and potential severity.
Balancing the need to control irAEs with maintaining the anti-tumor immune response is crucial.
Prompt diagnosis and treatment are essential to prevent severe or life-threatening complications.
2.Strategies to Manage irAEs:
Close monitoring: Patients receiving immunotherapy are closely monitored for early signs of irAEs.
Corticosteroids: Steroids like prednisone are commonly used to manage moderate to severe irAEs.
1. Immune suppression:
In some cases, immunosuppressive agents like infliximab or mycophenolate mofetil may be needed.
4.Treatment interruptions or discontinuations: In severe cases, treatment with checkpoint inhibitors may need to be temporarily halted or permanently discontinued.

FUTURE DIRECTIONS AND AREAS OF RESEARCH

Immunotherapy is a rapidly evolving field in cancer treatment, and ongoing research is exploring various directions to improve its applicability.

1. Personalized Immunotherapy:
Direction: Tailoring immunotherapy approaches based on a patient's unique tumor characteristics, genetic profile, and immune response to maximize treatment efficacy.[81]
2. Neoantigen Vaccines:
Direction: Developing personalized cancer vaccines targeting neoantigens—mutations unique to an individual's tumor—to stimulate a specific and potent immune response.
3. Combining Immunotherapies:[82]
Direction: Exploring the synergy of combining different immunotherapies, such as immune checkpoint inhibitors, adoptive cell therapies, and cytokines, to enhance treatment responses.[83]
4. Identifying Predictive Biomarkers:
Direction: Discovering and validating biomarkers that can accurately predict patient responses to immunotherapy, aiding treatment selection.[84]
5. Targeting Immune Checkpoints Beyond PD-1/PD-L1:
Direction: Investigating and developing therapies targeting emerging immune checkpoints like TIM-3, LAG-3, and TIGIT to expand the scope of immunotherapy.[85]
6. Enhancing CAR-T Cell Therapies:
Direction: Improving the safety, efficacy, and applicability of chimeric antigen receptor (CAR) T-cell therapies by optimizing CAR design, targeting solid tumors, and managing cytokine release syndrome.[86]

7. Modulating the Tumor Microenvironment:

Direction: Developing strategies to modify the immunosuppressive tumor microenvironment to enhance immune cell infiltration and activity.[87]

8. Overcoming Resistance Mechanisms:

Direction: Investigating and developing therapies to overcome resistance to immunotherapy, including strategies to target immune escape mechanisms.[88]

9. Pediatric Immunotherapy:

Direction: Extending the use of immunotherapy to pediatric cancers and addressing unique challenges in treating children.[89]

10. Artificial Intelligence (AI) and Predictive Modeling:

Direction: Leveraging AI and machine learning to analyze complex data, identify new therapeutic targets, and predict patient responses to treatment.[90]

11. Pediatric Precision Oncology:

Immunotherapy is increasingly being applied to pediatric cancers, emphasizing the importance of personalized approaches in pediatric oncology. Tailoring treatments to a child's unique genetic and immune makeup is crucial for minimizing side effects and maximizing effectiveness.[91]

CONCLUSION

CURRENT PROGRESS AND SIGNIFICANCE OF IMMUNOTHERAPY IN CANCER TREATMENT

Immunotherapy has made significant progress and has come a foundation in cancer treatment. It has revolutionized the way we approach colorful types of cancer.

Current Progress in Immunotherapy:

- Immune Checkpoint inhibitors: medicines that block vulnerable checkpoints like PD- 1, PD- L1, and CTLA- 4 have shown remarkable success in multiple cancer types. These impediments unleash the body's vulnerable system to target and destroy cancer cells.
- CAR-T Cell Therapy: chimeric Antigen Receptor T- cell remedy(Auto- T) has proven largely effective in treating certain hematologic malice, similar as acute lymphoblastic leukemia(ALL) and some tubercles.
- Personalized Vaccines:Personalized cancer vaccines that target specific excrescence antigens(neoantigens) are showing pledge, especially in carcinoma and some other solid excrescences.
- Tumor-Infiltrating Lymphocytes(TILs): TIL remedy involves rooting , expanding, and reinfusing a case's own vulnerable cells into the excrescence point. This approach has been successful in treating carcinoma.
- Combination Therapies: Combining different immunotherapies, immunotherapy with traditional treatments like chemotherapy or radiation, or binary vulnerable checkpoint leaguer has led to enhanced responses.
- Liquid Biopsies:Liquid Biopsies which dissect circulating excrescence DNA(ctDNA), are getting precious tools for monitoring treatment response and detecting early signs of relapse.

SIGNIFICANCE OF IMMUNOTHERAPY IN CANCER TREATMENT:

Durable Responses: Immunotherapy can lead to long- lasting remittals and indeed cures in some cancer cases, furnishing stopgap for those with advanced or preliminarily untreatable conditions.

*Fewer Side Effects: Immunotherapy frequently causes smaller side goods than traditional treatments like chemotherapy, as it targets cancer cells specifically and spares health.

*Expanding Indications: Immunotherapy is now approved for colorful cancer types, including carcinoma, lung cancer, bladder cancer, order cancer, head and neck cancer, and more.

*Survival Benefits: Immunotherapy has significantly bettered survival rates and overall issues in several cancer types, contributing to more patient quality of life.

*Personalization: The capability to epitomize treatment grounded on a case's vulnerable profile and excrescence characteristics is advancing perfection drug.

REFERENCE:

1.Sharma, P., & Allison, J. P. (2015). The future of immune checkpoint therapy. Science, 348(6230), 56-61.
2.Pardoll, D. M. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nature reviews Cancer, 12(4), 252-264.
3. Gabrilovich, D. I., & Nagaraj, S. (2009). Myeloid-derived suppressor cells as regulators of the immune system. Nature Reviews Immunology, 9(3), 162-174.
4.Ostrand-Rosenberg, S., & Fenselau, C. (2018). Myeloid-derived suppressor cells: immune-suppressive cells that impair antitumor immunity and are sculpted by their environment. Journal of immunology, 200(2), 422-431.
5.McGranahan, N., & Swanton, C. (2017). Clonal heterogeneity and tumor evolution: past, present, and the future. Cell, 168(4), 613-628.
6.Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646-674.
7. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1-10. doi:10.1016/j.immuni.2013.07.012
8. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-264. doi:10.1038/nrc3239
9. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348(6230):62-68. doi:10.1126/science.aaa4967
10.Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14(10):1014-1022. doi:10.1038/ni.2703
11. Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56-61. doi:10.1126/science.aaa8172
12.Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348(6230):62-68. doi:10.1126/science.aaa4967
13.Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723. doi:10.1056/NEJMoa1003466
14.Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480(7378):480-489. doi:10.1038/nature10673
15.Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723. doi:10.1056/NEJMoa1003466.
16.Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-264. doi:10.1038/nrc3239.
17.Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627-1639. doi:10.1056/NEJMoa1507643.
18.Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158-168. doi:10.1056/NEJMra1703481.

19.Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707-723. doi:10.1016/j.cell.2017.01.017.

20.Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723. doi:10.1056/NEJMoa1003466.

21. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734-1736. doi:10.1126/science.271.5256.1734

22.Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517-2526. doi:10.1056/NEJMoa1104621.

23.Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158-168. doi:10.1056/NEJMra1703481.

24.Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345-1356. doi:10.1056/NEJMoa1709684.

25.Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-2454. doi:10.1056/NEJMoa1200690.

26. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002;99(19):12293-12297. doi:10.1073/pnas.192461099.

27.Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455-2465. doi:10.1056/NEJMoa1200694.

28.Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158-168. doi:10.1056/NEJMra1703481.

29.Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381(21):2020-2031. doi:10.1056/NEJMoa1910231.

30.Rosenberg, S. A. (2014). Adoptive cell transfer as personalized immunotherapy for human cancer. Science, 348(6230), 62-68.

31.June, C. H., & Sadelain, M. (2018). Chimeric antigen receptor therapy. New England Journal of Medicine, 379(1), 64-73.

32.Bendle, G. M., Linnemann, C., Hooijkaas, A. I., & Pasetto, A. (2016). Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nature Medicine, 22(5), 576-582.

33.Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H. et al. (2018). Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. New England Journal of Medicine, 378(5), 439-448.

34.Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N. et al. (2019). ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biology of Blood and Marrow Transplantation, 25(4), 625-638.

35.Sharma, P., & Allison, J. P. (2015). The future of immune checkpoint therapy. Science, 348(6230), 56-61.

36.Stadtmauer, E. A., Fraietta, J. A., Davis, M. M., Cohen, A. D., Weber, K. L., Lancaster, E. et al. (2020). CRISPR-engineered T cells in patients with refractory cancer. Science, 367(6481), eaba7365.

37.Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., ... & Suryani, S. (2018). Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. New England Journal of Medicine, 378(5), 439-448. doi:10.1056/NEJMoa1709866

38.Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., ... & Maziarz, R. T. (2019). Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. New England Journal of Medicine, 380(1), 45-56. doi:10.1056/NEJMoa1804980

39.Melief, C. J. (2008). "Cancer immunotherapy by dendritic cells." Immunity, 29(3), 372-383.

40.Palucka, K., & Banchereau, J. (2013). "Dendritic-cell-based therapeutic cancer vaccines." Immunity, 39(1), 38-48.

41.Duperret, E. K., & Weiner, D. B. (2018). "The promise of RNA interference-based therapies for the treatment of HIV-1." Retrovirology, 15(1), 1-10.
42.Hodi, F. S., et al. (2010). "Improved survival with ipilimumab in patients with metastatic melanoma." New England Journal of Medicine, 363(8), 711-723.
43.Sahin, U., & Türeci, Ö. (2018). "Personalized vaccines for cancer immunotherapy." Science, 359(6382), 1355-1360.
44.Villa, L. L., et al. (2006). "Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial." The Lancet Oncology, 6(5), 271-278.
45.Platanias, L. C. (2005). "Mechanisms of type-I- and type-II-interferon-mediated signalling." Nature Reviews Immunology, 5(5), 375-386.
46.Fyfe, G., et al. (1995). "Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy." Journal of Clinical Oncology, 13(3), 688-696.
47.Leonard, J. P., & Sherman, M. L. (1997). "Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production." Blood, 90(7), 2541-2548.
48.Feldmann, M., & Maini, R. N. (2003). "Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases." Nature Medicine, 9(10), 1245-1250.
49.Lee, D. W., & June, C. H. (2017). "Cytokine release syndrome in severe COVID-19." Science, 368(6490), 473-474.
50.June, C. H., et al. (2018). "CAR T cell immunotherapy for human cancer." Science, 359(6382), 1361-1365.
51.Pardoll DM. The leaguer of vulnerable checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12(4) 252- 264.
52. Weiner , Surana R, WangS. Monoclonal antibodies protean platforms for cancer immunotherapy. Nat Rev Immunol. 2010; 10(5) 317- 327.
53.June CH, SadelainM. fantastic Antigen Receptor remedy. N Engl J Med. 2018; 379(1) 64- 73.
54.Biron CA, Byron KS, Sullivan JL. Severe Herpesvirus Infections in an Adolescent without Natural Killer Cells. N Engl J Med. 1989; 320(26)1731-1735.
55.Postow Mama, Callahan MK, Wolchok JD. Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol. 2015; 33(17)1974-1982.
56.Chen DS, MellmanI. Oncology Meets Immunology The Cancer- Immunity Cycle. impunity. 2013; 39(1) 1- 10.
57.Russell SJ, Peng KW, Bell JC. Oncolytic Virotherapy. Nat Biotechnol. 2012; 30(7) 658- 670.
58.Dudley ME, Wunderlich JR, Yang JC, et al. Consanguineous cell transfer remedy followingnon-myeloablative but lymphodepleting chemotherapy for the treatment of cases with refractory metastatic carcinoma. J Clin Oncol. 2005; 23(10)2346-2357.
59.Slamon, D. J., Leyland-Jones, B., Shak, S., et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. The New England Journal of Medicine, 344(11), 783-792.
60.Mok, T. S., Wu, Y. L., Thongprasert, S., et al. (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. The New England Journal of Medicine, 361(10), 947-957.
61.Van Cutsem, E., Köhne, C. H., Láng, I., et al. (2011). Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. Journal of Clinical Oncology, 29(15), 2011-2019.
62.Scher, H. I., Fizazi, K., Saad, F., et al. (2012). Increased survival with enzalutamide in prostate cancer after chemotherapy. The New England Journal of Medicine, 367(13), 1187-1197.

63.Druker, B. J., Guilhot, F., O'Brien, S. G., et al. (2006). Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New England Journal of Medicine, 355(23), 2408-2417.
64.Chapman, P. B., Hauschild, A., Robert, C., et al. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New England Journal of Medicine, 364(26), 2507-2516.
65.Byrd, J. C., Furman, R. R., Coutre, S. E., et al. (2013). Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. New England Journal of Medicine, 369(1), 32-42.
66.Gettinger, S. N., Choi, J., Mani, N., et al. (2017). A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers. Nature Communications, 8(1), 1-9.
67.Arlauckas, S. P., Garris, C. S., Kohler, R. H., et al. (2017). In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. Science Translational Medicine, 9(389), eaal3604.
68.Binnewies, M., Roberts, E. W., Kersten, K., et al. (2018). Understanding the tumor immune microenvironment (TIME) for effective therapy. Nature Medicine, 24(5), 541-550.
69. Le, D. T., Uram, J. N., Wang, H., et al. (2015). PD-1 blockade in tumors with mismatch-repair deficiency. New England Journal of Medicine, 372(26), 2509-2520.
70.Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., et al. (2016). Mutations associated with acquired resistance to PD-1 blockade in melanoma. New England Journal of Medicine, 375(9), 819-829.
71.Hellmann, M. D., Ciuleanu, T. E., Pluzanski, A., et al. (2018). Nivolumab plus Ipilimumab in lung cancer with a high tumor mutational burden. New England Journal of Medicine, 378(22), 2093-2104.
72.Sharma, P., & Allison, J. P. (2015). The future of immune checkpoint therapy. Science, 348(6230), 56-61.
73.Pardoll, D. M. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews Cancer, 12(4), 252-264.
74.Ribas, A., & Wolchok, J. D. (2018). Cancer immunotherapy using checkpoint blockade. Science, 359(6382), 1350-1355.
75.Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016). Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nature Reviews Cancer, 16(5), 275-287.
76.Saluja, S., & Gadgeel, S. M. (2017). Understanding cost and value in cancer care: A review. JCO Oncology Practice, 13(2), e190-e197.
77.Keenan, T. E., & Tolaney, S. M. (2018). Role of immunotherapy in the treatment of breast cancer. JAMA Oncology, 4(7), 1009-1010.
78.Hammers, H. J., Plimack, E. R., Infante, J. R., et al. (2017). Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: The CheckMate 016 Study. Journal of Clinical Oncology, 35(34), 3851-3858.
79.Binnewies, M., Roberts, E. W., Kersten, K., et al. (2018). Understanding the tumor immune microenvironment (TIME) for effective therapy. Nature Medicine, 24(5), 541-550.
80.Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018). Immune-related adverse events associated with immune checkpoint blockade. New England Journal of Medicine, 378(2), 158-168.
81.Yarchoan, M., Johnson, B. A., Lutz, E. R., Laheru, D. A., & Jaffee, E. M. (2017). Targeting neoantigens to augment antitumour immunity. Nature Reviews Cancer, 17(4), 209-222.
82.Sahin, U., Derhovanessian, E., Miller, M., et al. (2017). Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature, 547(7662), 222-226.
83.Hodi, F. S., Chesney, J., Pavlick, A. C., et al. (2016). Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. The Lancet Oncology, 17(11), 1558-1568.
84.Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016). Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nature Reviews Cancer, 16(5), 275-287.
85.Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016). Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation. Immunity, 44(5), 989-1004.

86.Majzner, R. G., & Mackall, C. L. (2018). Tumor antigen escape from CAR T-cell therapy. Cancer Discovery, 8(10), 1219-1226.

87.Binnewies, M., Roberts, E. W., Kersten, K., et al. (2018). Understanding the tumor immune microenvironment (TIME) for effective therapy. Nature Medicine, 24(5), 541-550.

88.Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017). Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell, 168(4), 707-723.

89.Maude, S. L., Laetsch, T. W., Buechner, J., et al. (2018). Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. New England Journal of Medicine, 378(5), 439-448.

90.Esteva, A., Kuprel, B., Novoa, R. A., et al. (2017). Dermatologist-level classification of skin cancer with deep neural networks. Nature, 542(7639), 115-118.